SOLICITATION NOTICE
A -- Purchase CBDP inhibited serum samples to use as reference materials for method development on the aerotoxic syndrome project in the CTMD laboratory
- Notice Date
- 8/9/2012
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2012-Q-15012
- Archive Date
- 9/8/2012
- Point of Contact
- Vallerie M Redd, Phone: 770-488-2845
- E-Mail Address
-
gfj3@cdc.gov
(gfj3@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Center for Disease Control and Prevention (CDC), National Center for Environmental Health (NCEH), Division of Laboratory Sciences (DLS) intends to award a sole source purchase order to Netherlands Organization for Applied Scientific Research (TNO), Schoemakerstraat 97 (Building A), NL -2628 VK Delft, Netherlands. The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology). The period of performance for this procurement is 6 months. The purpose of this acquisition is to purchase CBDP inhibited serum samples to use as reference materials for method development on the aerotoxic syndrome project in the CTMD laboratory. A method for synthesizing CBDP-inhibited human serum corresponding to biomarkers of exposure to tricresyl phosphates will be developed by TNO and is not publicly available. TNO has demonstrated ability to synthesize this type of reference serum in the quality and quantity necessary for the task at hand. Previous contracts with this organization have provided adducted reference serum that was of usable purity and quality and was delivered on time. Other vendors do not have a synthesis method available for generating these materials to the quantity and quality required. TNO is the only vendor with a proven method for synthesizing adducted serum corresponding to biomarkers of aerotoxic syndrome. Thus, TNO is the only company that can be used. As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to TNO. However, firms that believe they can meet these requirements are encouraged to identify themselves and give written notice by providing a capability statement to the Contracting Officer by August 24, 2012. The Contracting Officer will not respond to verbal requests. All requests must be in writing. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquiries shall be sent to Vallerie Redd by email at gfj3@cdc.gov and reference solicitation number 2012-Q-15012 on the subject line.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2012-Q-15012/listing.html)
- Place of Performance
- Address: TBD, United States
- Record
- SN02832667-W 20120811/120810000422-8ee6be410c0b252eb8d4770f7d146951 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |